A Comprehensive Pan-Cancer Analysis Identiﬁes CEP55 as a Potential Oncogene and Novel Therapeutic Target

Sep 24, 2026

Uploaded by Theodore

Emerging evidence indicates CEP55, a centrosomal protein, functions as a potential oncogene across multiple human malignancies, yet its behavior has not been systematically assessed in a pan-cancer framework. This study integrates multi-database interrogation of CEP55 expression, links it with cancer stage, and performs survival analyses of CEP55 overexpression. It also evaluates genetic alterations, methylation status, immune cell infiltration effects, chemotherapy responses, and proposes molecular mechanisms. Results show CEP55 upregulation in tumors versus normal tissues, associated with poorer prognosis, altered tumor-immune microenvironment markers, and differential drug responsiveness, supporting CEP55 as a predictive biomarker and therapeutic target.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages21

Reading Time53 min

AccessFree to download

Introduction

Cancer context and need for biomarkers

Materials and Methods

Databases and analytical approaches

Results

CEP55 expression across cancers

Prognostic value and survival association

Genetic alterations and methylation status

Immune cell infiltration and chemokines

Chemotherapy response correlations

Proposed molecular mechanisms

Discussion

Oncogenic significance and therapeutic implications

Conclusion

CEP55 as biomarker and target

diagnostics Article A Comprehensive Pan-Cancer Analysis Identiﬁes CEP55 as a Potential Oncogene and Novel Therapeutic Target Mohamed Samir A. Zaki 1,†, Muhammad Alaa Eldeen 2, *,†, Waleed K. Abdulsahib 3, Ayed A. Shati 4, Youssef A. Alqahtani 4, Saleh M. Al-Qahtani 4, Hassan M. Otiﬁ 5, Ashwag Asiri 4, Hesham M. Hassan 5, Hebatallah Emam Mohammed Ahmed 6, Samy A. Dawood 4, Amr Negm 7,8 and Refaat A. Eid 5 Citation: Zaki, M.S.A.; Eldeen, M.A.; Abdulsahib, W.K.; Shati, A.A.; Alqahtani, Y.A.; Al-Qahtani, S.M.; Otiﬁ, H.M.; Asiri, A.; Hassan, H.M.; Emam Mohammed Ahmed, H.; et al. A Comprehensive Pan-Cancer Analysis Identiﬁes CEP55 as a Potential Oncogene and Novel Therapeutic Target. Diagnostics 2023, 13, 1613. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)diagnostics13091613 Academic Editors: Andrea De Giglio and Alessandro Di Federico Received: 25 February 2023 Revised: 27 March 2023 Accepted: 8 April 2023 Published: 2 May 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Anatomy Department, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia 2 Cell Biology, Histology & Genetics Division, Biology Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt 3 Pharmacology and Toxicology Department, College of Pharmacy, Al Farahidi University, Baghdad 00965, Iraq 4 Department of Child Health, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia 5 Pathology Department, College of Medicine, King Khalid University, Abha P.O. Box 62529, Saudi Arabia 6 Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Benha University, Banha 13511, Egypt 7 Department of Chemistry, College of Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia 8 Chemistry Department, Faculty of Science, Mansoura University, Mansoura 35516, Egypt * Correspondence: [dr.muhammadalaa@gmail.com](dr.muhammadalaa@gmail.com) † These authors equally contributed to this work. Abstract: Emerging research ﬁndings have shown that a centrosomal protein (CEP55) is a potential oncogene in numerous human malignancies. Nevertheless, no pan-cancer analysis has been conducted to investigate the various aspects and behavior of this oncogene in different human cancerous tissues. Numerous databases were investigated to conduct a detailed analysis of CEP55 . Initially, we evaluated the expression of CEP55 in several types of cancers and attempted to ﬁnd the correlation between that and the stage of the examined malignancies. Then, we conducted a survival analysis to determine the relationship between CEP55 overexpression in malignancies and the patient's survival. Furthermore, we examined the genetic alteration forms and the methylation status of this oncogene. Additionally, the interference of CEP55 expression with immune cell inﬁltration, the response to various chemotherapeutic agents, and the putative molecular mechanism of CEP55 in tumorigenesis were investigated. The current study found that CEP55 was upregulated in cancerous tissues versus normal controls where this upregulation was correlated with a poor prognosis in multiple forms of human cancers. Additionally, it inﬂuenced the level of different immune cell inﬁltration and several chemokines levels in the tumor microenvironment in addition to the response to several antitumor drugs. Herein, we provide an in-depth understanding of the oncogenic activities of CEP55, identifying it as a possible predictive marker as well as a speciﬁc target for developing anticancer therapies. Keywords: CEP55; pan-cancer; methylation; prognosis; tumor immunotherapy; bio

FAQs

What is the main objective of this pan-cancer analysis of CEP55?

To evaluate CEP55 expression patterns and characterize how CEP55 behaves across different human cancers, including its clinical relevance and underlying biological associations.

How is CEP55 connected to prognosis and patient survival?

The analysis includes survival assessment showing that CEP55 overexpression correlates with poor prognosis in multiple cancer types.

What additional biological aspects of CEP55 are investigated beyond expression?

The study examines genetic alterations, methylation status, effects on immune cell infiltration and chemokines in the tumor microenvironment, and associations with responses to various chemotherapeutic agents.

Sep 24, 2026

Uploaded by Theodore